Abstract
Aspirin usage as monotherapy in acute ischemic stroke has been well-documented as the therapeutic option for early stroke management and recurrent stroke prevention. Recent studies have shown the potential of aspirin combination (dual antiplatelet therapy with clopidogrel) in effectively decreasing the possibility of recurrent stroke. Despite the promising clinical effectiveness, a cost-effectiveness model was built to compare these two options.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
